Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S. (GENIL.IS)
Full history for every metric is available with a Kvantra account
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S. (GENIL.IS)
No price history available.
Key financial summary
Financials in TRYTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TRY m | - | - | - | - | - | - | - | - |
| Operating profit | TRY m | - | |||||||
| Net profit | TRY m | - | - | - | - | - | - | - | - |
| EPS reported | TRY | - | |||||||
| Operating cashflow per share | TRY | - | |||||||
| Capex per share | TRY | - | |||||||
| FCF per share | TRY | - | |||||||
| Free cash flow | TRY m | - | |||||||
| Net debt | TRY m | - | |||||||
| Book value equity | TRY m | - | |||||||
| Book value per share | TRY | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | TRY | - |
Financial summary
Financials in TRYTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S. (GENIL.IS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free